Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial

被引：14
|
作者：
Choi, Hyon K. [1 ]
Neogi, Tuhina [2 ]
Stamp, Lisa K. [3 ]
Terkeltaub, Robert [4 ,5 ]
Dalbeth, Nicola [6 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Boston Univ, Sch Med, Boston, MA 02118 USA
[3] Univ Otago, Christchurch, New Zealand
[4] VA San Diego Healthcare Syst, San Diego, CA USA
[5] Univ Calif San Diego, La Jolla, CA 92093 USA
[6] Univ Auckland, Auckland, New Zealand
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷 / 05期
关键词：
D O I：
10.1002/art.41638
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：721 / 724
页数：4
相关论文
共 50 条
  • [1] Cardiovascular Risk Management of Patients in the Febuxostat Versus Allopurinol Streamlined Trial (FAST)
    Jennings, Claudine G.
    Mackenzie, Isla S.
    Flynn, Rob
    Ford, Ian
    Nuki, George
    MacDonald, Thomas M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 452 - 453
  • [2] Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
    MacDonald, Thomas M.
    Ford, Ian
    Nuki, George
    Mackenzie, Isla S.
    De Caterina, Raffaele
    Findlay, Evelyn
    Hallas, Jesper
    Hawkey, Christopher J.
    Ralston, Stuart
    Walters, Matthew
    Webster, John
    McMurray, John
    Ruiz, Fernando Perez
    Jennings, Claudine G.
    BMJ OPEN, 2014, 4 (07):
  • [3] Febuxostat or Allopurinol in Patients with Gout Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)
    Alten, R.
    Mischkewitz, M.
    Nitschmann, S.
    INTERNIST, 2020, 61 (05): : 530 - 532
  • [4] Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat
    Shin, Anna
    Choi, Se Rim
    Han, Minji
    Ha, You-Jung
    Lee, Yun Jong
    Lee, Eun Bong
    Kang, Eun Ha
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 56
  • [5] Febuxostat vs allopurinol for gout: cardiovascular safety
    Reactions Weekly, 2021, 1858 (1) : 9 - 9
  • [6] No increased cardiovascular risk with febuxostat versus allopurinol
    Reactions Weekly, 2020, 1830 (1) : 10 - 10
  • [7] Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
    White, William B.
    Saag, Kenneth G.
    Becker, Michael A.
    Borer, Jeffrey S.
    Gorelick, Philip B.
    Whelton, Andrew
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1200 - 1210
  • [8] The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?
    Katsiki, Niki
    Borghi, Claudio
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) : 1853 - 1856
  • [9] FEBUXOSTAT VERSUS ALLOPURINOL STREAMLINED TRIAL (FAST): BASELINE CHARACTERISTICS OF THE RANDOMISED PATIENT POPULATION
    Mackenzie, I.
    MacDonald, T.
    Ford, I.
    Nuki, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1631 - 1631
  • [10] Diuretic use and serum urate levels in the Febuxostat versus Allopurinol Streamlined Trial (FAST)
    Flynn, Robert W. V.
    MacDonald, Thomas
    Ford, Ian
    Nuki, George
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 147 - 148
12345